Dr David Carl, MD | |
Benton City Clinic-prosser Memorial Health, 701 Dale Ave Suite A, Benton City, WA 99350 | |
(509) 588-4075 | |
(509) 588-4197 |
Full Name | Dr David Carl |
---|---|
Gender | Male |
Speciality | Pediatrics |
Location | Benton City Clinic-prosser Memorial Health, Benton City, Washington |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1972920080 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208000000X | Pediatrics | MD60763667 (Washington) | Primary |
Entity Name | Prosser Public Hospital District Of Benton County |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1306897681 PECOS PAC ID: 6709787872 Enrollment ID: O20040120000974 |
News Archive
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Advocates at a meeting in Paris about women, population and development, held ahead of next week's G8 summit, said that HIV prevention methods can be used to further family planning goals, Deutsche Welle reports.
City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.
The American Society of Anesthesiologists (ASA) today announced its strategic partnership with The Partnership at Drugfree.org's new national campaign, The Medicine Abuse Project, to prevent half a million teens from abusing drugs.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Dr David Carl, MD 723 Memorial St, Prosser, WA 99350-1524 Ph: (509) 786-2222 | Dr David Carl, MD Benton City Clinic-prosser Memorial Health, 701 Dale Ave Suite A, Benton City, WA 99350 Ph: (509) 588-4075 |
News Archive
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Advocates at a meeting in Paris about women, population and development, held ahead of next week's G8 summit, said that HIV prevention methods can be used to further family planning goals, Deutsche Welle reports.
City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.
The American Society of Anesthesiologists (ASA) today announced its strategic partnership with The Partnership at Drugfree.org's new national campaign, The Medicine Abuse Project, to prevent half a million teens from abusing drugs.
› Verified 3 days ago